SAP-001 is a novel, clinical stage (IIb) small molecule designed to address the large and growing unmet medical needs associated with refractory and tophaceous gout.

Chronic pruritus occurs in 13% of the global population without age limitation, leading to great impairment of quality of life. There is a high unmet need here as effective treatment options are still missing.